Literature DB >> 22364328

Pharmacological targeting of spreading depression in migraine.

Katharina Eikermann-Haerter1, Anil Can, Cenk Ayata.   

Abstract

Migraine, particularly with aura, is a genetically heterogeneous disorder of ion channels, pumps or transporters associated with increased cortical excitability. Spreading depression, as one reflection of hyperexcitability, is the electrophysiological event underlying aura symptoms and a trigger for headache. Endogenous (e.g., genes and hormones) and exogenous factors (e.g., drugs) modulating migraine susceptibility have also been shown to modulate spreading depression susceptibility concordantly, suggesting that spreading depression can be a relevant therapeutic target in migraine. In support of this, several migraine prophylactic drugs used in clinical practice have been shown to suppress spreading depression susceptibility as a probable mechanism of action, despite belonging to widely different pharmacological classes. Hence, susceptibility to spreading depression can be a useful preclinical model with good positive and negative predictive value for drug screening.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22364328      PMCID: PMC3321647          DOI: 10.1586/ern.12.13

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  87 in total

1.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

Review 2.  Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury.

Authors:  Martin Lauritzen; Jens Peter Dreier; Martin Fabricius; Jed A Hartings; Rudolf Graf; Anthony John Strong
Journal:  J Cereb Blood Flow Metab       Date:  2010-11-03       Impact factor: 6.200

3.  Spreading depression: from serendipity to targeted therapy in migraine prophylaxis.

Authors:  C Ayata
Journal:  Cephalalgia       Date:  2009-10       Impact factor: 6.292

4.  Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat.

Authors:  D P Bradley; M I Smith; C Netsiri; J M Smith; K H Bockhorst; L D Hall; C L Huang; R A Leslie; A A Parsons; M F James
Journal:  Exp Neurol       Date:  2001-12       Impact factor: 5.330

5.  Nitrous oxide for the treatment of acute migraine headache.

Authors:  W R Triner; J M Bartfield; M Birdwell; N Raccio-Robak
Journal:  Am J Emerg Med       Date:  1999-05       Impact factor: 2.469

Review 6.  Role of magnesium in the pathogenesis and treatment of migraines.

Authors:  A Mauskop; B M Altura
Journal:  Clin Neurosci       Date:  1998

7.  The effects of flunarizine in experimental models related to the pathogenesis of migraine.

Authors:  A Wauquier; D Ashton; R Marrannes
Journal:  Cephalalgia       Date:  1985-05       Impact factor: 6.292

8.  Estrogen administration increases neuronal responses to excitatory amino acids as a long-term effect.

Authors:  S S Smith
Journal:  Brain Res       Date:  1989-12-04       Impact factor: 3.252

9.  Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women.

Authors:  F Granella; G Sances; C Zanferrari; A Costa; E Martignoni; G C Manzoni
Journal:  Headache       Date:  1993 Jul-Aug       Impact factor: 5.887

10.  Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2.

Authors:  Loredana Leo; Lisa Gherardini; Virginia Barone; Maurizio De Fusco; Daniela Pietrobon; Tommaso Pizzorusso; Giorgio Casari
Journal:  PLoS Genet       Date:  2011-06-23       Impact factor: 5.917

View more
  10 in total

1.  Intranasally administered IGF-1 inhibits spreading depression in vivo.

Authors:  Yelena Y Grinberg; Lois A Zitzow; Richard P Kraig
Journal:  Brain Res       Date:  2017-09-23       Impact factor: 3.252

2.  Determinants of Optogenetic Cortical Spreading Depolarizations.

Authors:  David Y Chung; Homa Sadeghian; Tao Qin; Sevda Lule; Hang Lee; Fahri Karakaya; Stacy Goins; Fumiaki Oka; Mohammad A Yaseen; Thijs Houben; Else A Tolner; Arn M J M van den Maagdenberg; Michael J Whalen; Sava Sakadžic; Cenk Ayata
Journal:  Cereb Cortex       Date:  2019-03-01       Impact factor: 5.357

Review 3.  Spreading Depression in Primary and Secondary Headache Disorders.

Authors:  Shih-Pin Chen; Cenk Ayata
Journal:  Curr Pain Headache Rep       Date:  2016-07

Review 4.  Migraine and Neuroticism: A Scoping Review.

Authors:  Carmen M Galvez-Sánchez; Casandra I Montoro Aguilar
Journal:  Behav Sci (Basel)       Date:  2022-01-28

5.  Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine.

Authors:  Raffaele Palmirotta; Piero Barbanti; Cristiano Ialongo; Maria Laura De Marchis; Jhessica Alessandroni; Gabriella Egeo; Cinzia Aurilia; Luisa Fofi; Maria Giovanna Valente; Patrizia Ferroni; David Della-Morte; Fiorella Guadagni
Journal:  DNA Cell Biol       Date:  2014-12-10       Impact factor: 3.311

6.  Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues.

Authors:  Levente Knapp; Bence Szita; Kitti Kocsis; László Vécsei; József Toldi
Journal:  Drug Des Devel Ther       Date:  2016-12-20       Impact factor: 4.162

Review 7.  Potential Application of Optogenetic Stimulation in the Treatment of Pain and Migraine Headache: A Perspective from Animal Studies.

Authors:  Sufang Liu; Yuanyuan Tang; Ying Xing; Phillip Kramer; Larry Bellinger; Feng Tao
Journal:  Brain Sci       Date:  2019-01-29

Review 8.  Spreading depression as a preclinical model of migraine.

Authors:  Andrea M Harriott; Tsubasa Takizawa; David Y Chung; Shih-Pin Chen
Journal:  J Headache Pain       Date:  2019-05-02       Impact factor: 7.277

9.  Vagus nerve stimulation inhibits cortical spreading depression.

Authors:  Shih-Pin Chen; Ilknur Ay; Andreia Lopes de Morais; Tao Qin; Yi Zheng; Homa Sadeghian; Fumiaki Oka; Bruce Simon; Katharina Eikermann-Haerter; Cenk Ayata
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

Review 10.  Cortical spreading depression as a target for anti-migraine agents.

Authors:  Cinzia Costa; Alessandro Tozzi; Innocenzo Rainero; Letizia Maria Cupini; Paolo Calabresi; Cenk Ayata; Paola Sarchielli
Journal:  J Headache Pain       Date:  2013-07-23       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.